Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance

Cancer Letters

Volumn 178, Issue 2, 2002, Pages 141-149

  Lotfi, Kourosh ^a   Zackrisson, Anna Lena ^a   Peterson, Curt ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Cytotoxicity; Daunorubicin; Idarubicin; Intracellular accumulation; MOLT 4

Indexed keywords

BROMINE DERIVATIVE; DAUNORUBICIN; FLUORESCEIN ISOTHIOCYANATE; IDARUBICIN; LIPOCORTIN 5; VERAPAMIL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG UPTAKE; GENE EXPRESSION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL SURVIVAL; DAUNORUBICIN; DRUG RESISTANCE; DRUG RESISTANCE, NEOPLASM; HUMANS; IDARUBICIN; LEUKEMIA; TUMOR CELLS, CULTURED;

EID: 0037171580     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00824-2     Document Type: Article

References (44)

1. Anthracycline analogs: The past, present, and future
2. Anthracycline and anthraquinone anticancer agents: Current status and recent developments
3. Idarubicin v daunorubicin: Preclinical and clinical pharmacokinetic studies
4. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia
5. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study
6. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
7. ABC transporters from microorganisms to man
8. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells
9. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
10. Apoptosis and the dilemma of cancer chemotherapy
11. Chemotherapy-induced apoptosis
12. Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells
13. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells
14. Biochemical pharmacology and resistance to 2-chloro-2′-arabinofluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells
15. A simple salting out procedure for extracting DNA from human nucleated cells
16. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
17. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V
18. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line
19. Biochemistry of multidrug resistance mediated by the multidrug transporter
20. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia
21. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin
22. Regulation of c-jun gene expression in HL-60 leukemia cells by 1-beta-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism
23. 1-Beta-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells
24. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
25. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias
26. Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells
27. Effect of some antibiotics on eukaryotic DNA methylation in vitro and in vivo
28. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents
29. Idarubicin overcomes P-glycoprotein-related multidrug resistance: Comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
30. Development of drug resistance is reduced with idarubicin relative to other anthracyclines
31. Idarubicin DNA intercalation is reduced by MRP1 and not Pgp
32. Characterization of drug-resistant cell lines by comparative genomic hybridization
33. Effects of daunorubicin on cell growth, cell cycle and induction of apoptosis in HL-60 cells
34. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells
35. DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells
36. Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells
37. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells
38. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia
39. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells
40. Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumour cells in culture
41. Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: Factors contributing to drug-induced cell death and reversal of multidrug resistance
42. Analysis of drug transport kinetics in multidrug-resistant cells: Implications for drug action
43. Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysis
44. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells